The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 03, 2019
Filed:
Apr. 29, 2015
Applicant:
Whitehead Institute for Biomedical Research, Cambridge, MA (US);
Inventors:
Diwakar Pattabiraman, Cambridge, MA (US);
Brian Bierie, Cambridge, MA (US);
Wai Leong Tam, Singapore, SG;
Robert A. Weinberg, Brookline, MA (US);
Assignee:
Whitehead Institute for Biomedical Research, Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/352 (2006.01); A61K 31/35 (2006.01); G01N 33/50 (2006.01); A61K 31/704 (2006.01); C12N 5/00 (2006.01); C12N 5/095 (2010.01);
U.S. Cl.
CPC ...
A61K 31/352 (2013.01); A61K 31/704 (2013.01); C12N 5/0093 (2013.01); C12N 5/0695 (2013.01); G01N 33/5011 (2013.01); G01N 33/5041 (2013.01); G01N 33/5073 (2013.01); C12N 2501/727 (2013.01); C12N 2506/30 (2013.01); G01N 2333/91205 (2013.01); G01N 2800/52 (2013.01); Y02A 50/471 (2018.01);
Abstract
Aspects of the disclosure relate to methods that involve activating the Protein Kinase A (PKA) pathway to induce cancer stem cells (CSCs) to undergo a mesenchymal to epithelial transition. Methods provided herein are useful, in some embodiments, because they render CSCs amenable to treatment with conventional cancer therapies. In some embodiments, methods are provided that involve assaying PKA pathway activity to identify compounds that selectively target CSCs.